Cloning and Mutagenesis Market
Number of pages: 100 | Report Format: PDF | Published date: March 24, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.45 billion |
|
Revenue Forecast in 2031 |
US$ 10.15 billion |
|
CAGR |
17.12% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Product, Technology, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global cloning and mutagenesis market was valued at US$ 2.45 billion in 2022 and is expected to register a revenue CAGR of 17.12% to reach US$ 10.15 billion by 2031.
Cloning and Mutagenesis Market Fundamentals
The cloning and mutagenesis market refers to the commercial sector involved in developing, manufacturing, and distributing products and services related to cloning and mutagenesis technologies. Cloning refers to creating copies of a DNA fragment or an entire organism. In molecular biology, cloning usually refers to creating copies of a specific DNA fragment, which is then inserted into a vector (usually a plasmid) that can replicate in a host organism (such as a bacterium or yeast). The resulting construct, a recombinant plasmid, can produce multiple copies of the DNA fragment. Mutagenesis, on the other hand, refers to the process of inducing changes in the DNA sequence of an organism or a fragment of DNA. These changes can be intentional, such as site-directed mutagenesis, where specific mutations are introduced into a gene or DNA fragment, or they can be random, such as mutagenesis induced by chemicals or radiation. The market revenue growth is primarily driven by the increasing demand for genetically modified organisms (GMOs) in various industries such as agriculture, healthcare, and biotechnology. The major players operating in the cloning and mutagenesis market include Thermo Fisher Scientific Inc., GenScript Biotech Corporation, Agilent Technologies, Inc., Merck KGaA, Takara Bio Inc., Promega Corporation, New England Biolabs, Inc., Integrated DNA Technologies, Inc., and Genewiz, Inc.
[45756]
Cloning and Mutagenesis Market Dynamics
Cloning and mutagenesis are important molecular biology techniques widely used in research, pharmaceuticals, and agriculture. The cloning market includes various products and services, such as vectors, cloning kits, enzymes, and synthetic biology tools. The mutagenesis segment includes products and services for site-directed mutagenesis, random mutagenesis, and other types of mutagenesis.
The global cloning and mutagenesis market is projected to grow significantly over the forecast period due to the rising incidence of diseases like cancer and HIV and genetic diseases globally. For instance, the WHO reports cardiovascular illnesses are responsible for an estimated 17.9 million fatalities annually. Cancer is another major cause of death globally, accounting for around one in six deaths. In the case of cancer, customized medicine uses unique information about a patient’s tumor to help with diagnosis, plan treatment, determine the effect of the treatment, and determine the prognosis.
By adopting cutting-edge methods for developing treatments, kits, and vaccines for COVID-19, many significant biotechnology and pharmaceutical businesses and makers of cloning and mutagenesis kits have intensified their R&D activities globally. For instance, the National Medical Products Administration of China granted CanSino Biologics Inc. approval in September 2022 for the emergency usage of an inhalable COVID-19 vaccination with an adenovirus. The S protein’s full-length gene and an improved plasminogen activator signal peptide gene were cloned into the Ad5 vector to create it. These factors are driving the revenue growth of the global cloning and mutagenesis market.
The adoption of cloning and mutagenesis technologies, such as PCR, will likely rise in the coming years due to the increasing demand for personalized medicine. For instance, Genes2Me introduced a molecular product line in November 2021 that includes, among other product categories, cloning, next-generation technology, and enzyme technology. The product line’s Fantom High-Fidelity PCR DNA polymerase may significantly boost PCR test sensitivity, giving it a practical basis for cloning technology. Hence, during the projected period, rising demand for personalized medicine will likely drive the revenue growth of global cloning and mutagenesis.
Growing consumer demand for crops and other products made with genetic engineering is boosting the revenue growth of the global cloning and mutagenesis market. Insect-resistant and herbicide-tolerant seeds that have undergone genetic modification have become extremely popular, and crops have quickly adapted to them, aiding in the expansion of the agricultural sector. Cloning and mutagenesis have made it possible to modify crops’ genetic makeup, increase soil production, and effectively combat pests. For instance, the Genetic Engineering Appraisal Committee authorized the commercial release of GM mustard in October 2022. This program is anticipated to spur agricultural improvement to suit dietary needs.
However, the revenue growth of the global cloning and mutagenesis market may also be impacted by several other variables, including the high cost of cloning and mutagenesis technologies, ethical issues with the usage of genetically modified organisms, and stringent regulatory policies.
Cloning and Mutagenesis Market Ecosystem
The global cloning and mutagenesis market has been analyzed from four perspectives: product, technology, end-user, and region.
Cloning and Mutagenesis Market by Product
[75445]
Based on product, the global cloning and mutagenesis market has been segmented into mutagenesis kits, cloning kits, and others.
The mutagenesis kits segment is projected to record a high revenue CAGR in the forecast period. Mutagenesis kits are utilized in various scientific tasks, such as cloning DNA, researching the effects of mutagens, and creating proteins. Also, these kits are used in medical settings to treat and research conditions, such as cancer and HIV, and assist immunocompromised individuals. Thus, the market is driven by the growing usage of mutagenesis kits in biomedical research and increasing kit usage in R&D activities.
Cloning and Mutagenesis Market by Technology
Based on technology, the global cloning and mutagenesis market has been segmented into site-directed mutagenesis, TOPO PCR cloning, seamless cloning, blunt-end cloning, and others.
The TOPO PCR cloning segment accounts for the largest revenue share in the global cloning and mutagenesis market. This method uses DNA topoisomerase. It’s biological activity to clone DNA fragments into vectors. This method has several benefits over conventional TA cloning, including ligation and restriction-free cloning, simple primer design, no need for post-PCR steps, and higher efficiency. Due to this, TOPO PCR cloning is seeing increased use across various end users, including pharmaceutical and biotech corporations and academic and research institutions.
The site-directed mutagenesis segment will record a high revenue CAGR during the forecast period. The DNA sequence of a gene can be intentionally and specifically modified using site-directed mutagenesis technology. This method has applications in genetic research, gene technology, and protein engineering by permitting precise gene and protein editing. Furthermore, leading market players offer innovative site-directed mutagenesis-based kits that streamline and expedite the process. One effective and adaptable technique for introducing point mutations, insertions, or deletions into any form of plasmid DNA is the Phusion Site-Directed Mutagenesis Kit provided by Thermo Fisher Scientific, Inc. Such site-directed mutagenesis-based product offers are anticipated to promote market expansion in the coming years.
Cloning and Mutagenesis Market by End User
Based on end user, the global cloning and mutagenesis market has been segmented into CROs & CMOs, biopharmaceutical companies, and academic & research institutes.
The biopharmaceutical companies segment accounts for the largest revenue share in the global cloning and mutagenesis market. Due to the increased prevalence of diseases, pharmaceutical and biopharmaceutical organizations are concentrating on drug discovery and development. Cloning and mutagenesis techniques help in the therapeutic modulation of disease-associated genes. In the preclinical stage of drug discovery, cloning is most appropriate for pharmacologic compounds. Growth hormone, erythropoietin, synthetic insulin, and vaccination are successful therapeutic products derived via cloning. Also, by supplying fresh cells for tissue engineering and transplantation, these methods profoundly impact human therapies. Such broad applications of cloning and mutagenesis in the biopharmaceutical and pharmaceutical industry drive segment revenue growth.
The CROs and CMOs segment is projected to grow at a high revenue CAGR during the forecast period. Pharmaceutical and biopharmaceutical companies outsource cloning and mutagenesis to CROs and CMOs for numerous reasons. These outsourcing initiatives have the potential to save time and increase productivity. Several CROs and CMOs offer cloning and mutagenesis services to pharmaceutical and biopharmaceutical companies. Some leading service providers in the market are ALLELE LIFE SCIENCES, Azenta Life Sciences, Charles River Laboratories, Luminous BioSciences, LLC, and OriGene Technologies, Inc. Azenta Life Sciences, for instance, provides specific technical support for applications, such as bespoke DNA constructions.
Cloning and Mutagenesis Market by Region
Based on region, the global cloning and mutagenesis market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the largest revenue share of the global cloning and mutagenesis market. The rising demand for biotechnology methods is majorly responsible for this significant percentage. Also, cloning and mutagenesis procedures have increased due to the region’s greater acceptance of platforms built on genomic and proteomic data. Due to the presence of key market players and inventors in the region, the products are now more prevalent. In May 2021, Telesis Bio, Inc., a U.S. company, announced, for instance, that its BioXp technology now offers lengthy fragment cloning. This project enables researchers to build multivariant, error-corrected vectors and hand-free overnight clone them into custom vectors.
The Asia Pacific market is projected to progress at a higher revenue CAGR during the forecast period. This is because there is a growing need for innovative therapies in the region. Other elements promoting regional revenue growth include a better economy, more government investment in R&D, and accelerating infrastructure development. Also, funding is being provided for developing a cure for several chronic illnesses, including cancer, by several market players.
Cloning and Mutagenesis Market Competitive Landscape
The prominent players operating in the global cloning and mutagenesis market are:
Cloning and Mutagenesis Market Strategic Developments
The global cloning and mutagenesis market is expected to register growth at a revenue CAGR of 17.12% in the forecast period.
Thermo Fisher Scientific, Inc., Merck Millipore, Bio-Rad Laboratories, Inc., Takara Bio Inc., and Danaher Corporation are among the key players in the global cloning and mutagenesis market.
The rising number of chronic and genetic diseases, personalized medicine, and the growing focus on protein engineering for drug development are driving the global cloning and mutagenesis market revenue growth.
Asia Pacific is expected to register the highest revenue growth in the global cloning and mutagenesis market during the forecast period.
The global cloning and mutagenesis market was valued at US$ 2.45 billion in 2022.
*Insights on financial performance are subject to the availability of information in the public domain